用于治疗转移性黑色素瘤的新型双环二酰甘油激酶抑制剂
Novel Bicyclic DGK Inhibitors for Treating Metastatic Melanoma.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2025 Apr 2;16(5):728-729. doi: 10.1021/acsmedchemlett.5c00164. eCollection 2025 May 8.
Abstract
Provided herein are novel bicyclic DGK inhibitors, pharmaceutical compositions, use of such compounds in treating metastatic melanoma, and processes for preparing such compounds.
摘要
本文提供了新型双环二酰甘油激酶（DGK）抑制剂、药物组合物、此类化合物在治疗转移性黑色素瘤中的用途以及制备此类化合物的方法。
相似文献
1
Novel Bicyclic DGK Inhibitors for Treating Metastatic Melanoma.用于治疗转移性黑色素瘤的新型双环二酰甘油激酶抑制剂
ACS Med Chem Lett. 2025 Apr 2;16(5):728-729. doi: 10.1021/acsmedchemlett.5c00164. eCollection 2025 May 8.
2
Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic Melanoma.新型杂芳基氟代烯烃作为治疗癌症尤其是转移性黑色素瘤的二酰甘油激酶（DGK）抑制剂
ACS Med Chem Lett. 2024 Aug 22;15(9):1433-1434. doi: 10.1021/acsmedchemlett.4c00409. eCollection 2024 Sep 12.
3
Novel Bicyclic Amines as CDK2 Inhibitors for Treating Metastatic Breast Cancer or Metastatic Lung Cancer.新型双环胺类化合物作为治疗转移性乳腺癌或转移性肺癌的细胞周期蛋白依赖性激酶2（CDK2）抑制剂
ACS Med Chem Lett. 2025 Jan 16;16(2):198-199. doi: 10.1021/acsmedchemlett.5c00005. eCollection 2025 Feb 13.
4
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.作为用于治疗癌症的CD73抑制剂的新型双环杂环化合物。
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
5
Bicyclic Ureas as JAK2 Inhibitors for Treating Hematological Cancer.双环脲类化合物作为治疗血液系统癌症的JAK2抑制剂
ACS Med Chem Lett. 2024 Oct 29;15(11):1824-1825. doi: 10.1021/acsmedchemlett.4c00496. eCollection 2024 Nov 14.
6
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.作为治疗炎症性疾病的MRGPRX2拮抗剂的新型双环杂环化合物
ACS Med Chem Lett. 2025 Apr 2;16(5):732-733. doi: 10.1021/acsmedchemlett.5c00165. eCollection 2025 May 8.
7
Novel Bicyclic Heterocycles as MRGPRX2 Antagonists for Treating Inflammatory Diseases.新型双环杂环化合物作为治疗炎症性疾病的MRGPRX2拮抗剂
ACS Med Chem Lett. 2025 Jun 2;16(6):980-981. doi: 10.1021/acsmedchemlett.5c00305. eCollection 2025 Jun 12.
8
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
9
Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.用于治疗自身免疫性和炎性疾病的新型酪氨酸激酶2（TYK2）抑制剂
ACS Med Chem Lett. 2024 Dec 9;16(1):8-9. doi: 10.1021/acsmedchemlett.4c00566. eCollection 2025 Jan 9.
10
MALT1 Inhibitors for Treating Cancer and Immunological Diseases.用于治疗癌症和免疫疾病的MALT1抑制剂
ACS Med Chem Lett. 2024 Aug 20;15(9):1419-1420. doi: 10.1021/acsmedchemlett.4c00390. eCollection 2024 Sep 12.
本文引用的文献
1
Exosomal Lipids in Cancer Progression and Metastasis.外泌体脂质在癌症进展和转移中的作用
Cancer Med. 2025 Mar;14(6):e70687. doi: 10.1002/cam4.70687.
2
The dynamic regulatory network of phosphatidic acid metabolism: a spotlight on substrate cycling between phosphatidic acid and diacylglycerol.磷脂酸代谢的动态调控网络：聚焦于磷脂酸和二酰基甘油之间的底物循环。
Biochem Soc Trans. 2024 Oct 30;52(5):2123-2132. doi: 10.1042/BST20231511.
3
Atypical MAPKs in cancer.癌症中的非典型丝裂原活化蛋白激酶
FEBS J. 2025 May;292(9):2173-2188. doi: 10.1111/febs.17283. Epub 2024 Sep 30.
4
Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic Melanoma.新型杂芳基氟代烯烃作为治疗癌症尤其是转移性黑色素瘤的二酰甘油激酶（DGK）抑制剂
ACS Med Chem Lett. 2024 Aug 22;15(9):1433-1434. doi: 10.1021/acsmedchemlett.4c00409. eCollection 2024 Sep 12.
5
The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedside.天然产物针对代谢紊乱的细胞和分子靶点：通向临床应用的转化方法。
MedComm (2020). 2024 Jul 24;5(8):e664. doi: 10.1002/mco2.664. eCollection 2024 Aug.
6
Diacylglycerol kinases: A look into the future of immunotherapy.二酰甘油激酶：免疫疗法的未来展望。
Adv Biol Regul. 2024 Jan;91:100999. doi: 10.1016/j.jbior.2023.100999. Epub 2023 Nov 2.
Zotero 插件